Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 6,229 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Metabolic Dysfunction-associated Steatohepatitis (MASH)
Interventions: VV-14303; Genetic
Lead sponsor: Kriya Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Chandler, Arizona • Lady Lake, Florida

Conditions: Obesity
Interventions: Financial incentive; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 30 Years to 80 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions: NPT 2042 (bumetanide analog) or Matching Placebo; Drug
Lead sponsor: NeuroPro Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Harm Reduction, Naloxone, Opioid Overdose
Interventions: VENDY; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Not listed
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Denver, Colorado • Frisco, Colorado • Pueblo, Colorado

Conditions: Smoking
Interventions: Smart Phone App, NIcotine Patches; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sleep, Nightshift Work
Interventions: Single-Sensor Tracking (In-Lab), Multi-Sensor Sleep Tracking (In-Lab), Multi-Sensor Sleep Tracking (At-Home); Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Postsurgical Pain
Interventions: CA-008 (vocacapsaicin), Placebo; Drug
Lead sponsor: Concentric Analgesics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 11
States / cities: Clovis, California • Los Angeles, California • Newport Beach, California + 6 more

Conditions: Traumatic Brain Injury
Interventions: Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI; Drug · Device · Other + 1 more
Lead sponsor: Uniformed Services University of the Health Sciences; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Relacorilant, Enzalutamide, Placebo (Sugar Pill), Androgen Deprivation Therapy, Radical Prostatectomy; Drug · Other · Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Chicago, Illinois • Evanston, Illinois • Portland, Oregon + 1 more

Conditions: Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer
Interventions: Ibrutinib, Durvalumab; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 17
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 13 more

Conditions: HIV, Alcohol Use
Interventions: IMB-motivational interviewing (MI) techniques (IMB-MI); Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Interventions: AZD 1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more

Conditions: Advanced Solid Tumor
Interventions: SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 5 more

Conditions: Out-Of-Hospital Cardiac Arrest
Interventions: igel, Compression Rate; Device · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Volunteers, Anemia, Sickle Cell
Interventions: AG-946, AG-946 Matched Placebo; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: La Jolla, California • Boston, Massachusetts • New York, New York + 4 more

Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
Interventions: NNC0487-0111, Semaglutide, Placebo (matched to NNC0487-0111), Placebo (matched to semaglutide); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 985 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Hollywood, Florida • Orange City, Florida • Weston, Florida + 7 more

Conditions: Sleep Deprivation
Interventions: Sleep Deprivation, Heart Rate, Sleep Monitoring, Diet, Exercise Performance, Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index, Cognitive performance, Marksmanship Performance, Quick Board, Advanced Medical Technologies Inc, Jump Test, CGM/CKM, Blood Draw, Ketone Supplement; Other · Behavioral · Biological + 1 more
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Coronary Artery Disease
Interventions: [O-15]-Water PET Myocardial Perfusion Imaging (MPI); Drug
Lead sponsor: MedTrace Pharma A/S; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Iowa City, Iowa • Rochester, Minnesota • St Louis, Missouri + 3 more

Conditions: HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Interventions: Denikitug, Nivolumab, Ramucirumab, Paclitaxel; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: Boston, Massachusetts • Albany, New York • New York, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1614235, Sitagliptin, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miami, Florida • Baton Rouge, Louisiana • Cincinnati, Ohio

Conditions: Active Ulcerative Colitis
Interventions: Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Chula Vista, California • Miami, Florida

Conditions: Rett Syndrome
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 3 Years to 18 Years · Female only
Enrollment: 146 participants
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Diabetes Mellitus, Type 1 Diabetes
Interventions: Culturally and linguistically tailored onboarding and support program, Medtronic MiniMed 780G Insulin Pump System; Other · Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 20 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)

Financial Incentives for Maintenance of Weight Loss

Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects

Vending Machine Naloxone Distribution for Your Community (VENDY)

Smartphone-delivered Scheduled Smoking With Compliance Facilitation as an Adjunct Cessation Therapy: a Feasibility Study

The Use of Multiple Sensors to Track Sleep in Nightshift Workers

Preliminary Study of CA-008 (Vocacapsaicin) in Patients Undergoing Ventral Hernia Repair

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 1

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Study of SRF617 in Patients With Advanced Solid Tumors

First Responder Airway & Compression Rate Trial

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Strategies to Augment Ketosis: Ketone Conferred Resiliency Against Sleep Restriction

RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

Development of a Behavioral Outcome Measure for Rett Syndrome (RettBe)

Supporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative